MedPath

Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis

Phase 4
Completed
Conditions
Atopic Dermatitis
Psoriasis
Interventions
Other: no educational program
Behavioral: education on skin disease conditions
Behavioral: Stress-reduction techniques
Behavioral: Lifestyle factors and psycho-education
Registration Number
NCT01077882
Lead Sponsor
University Hospital, Ghent
Brief Summary

'OnderHUIDs' is an educational program (Department of Dermatology, University Hospital, Gent) for patients with psoriasis and atopic dermatitis. We want to stimulate the patient to actively participate in their therapeutic approach by enhanced self care. We call the hypothesis that this program will help the patients learn to cope with their disease and to be loyal to their treatment, which will result in a better quality of life, better clinical outcome and cost effectiveness.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patients who have given written informed consent
  • Women or men of any race
  • Patients who are 18-75 years of age
  • Diagnosis of psoriasis or atopic dermatitis
Exclusion Criteria
  • Patients with a cognitive disorder (not able to understand, speak, read or write..)
  • Patients with a significant underlying medical cause (i.e. severe infection, haematologic disease, malignity, severe renal or hepatic disease, major depression) in the last 3 months
  • Patients under experimental pharmaceutical medication

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
current therapyno educational program-
current therapy with educational programLifestyle factors and psycho-education-
current therapy with educational programStress-reduction techniques-
current therapy with educational programeducation on skin disease conditions-
Primary Outcome Measures
NameTimeMethod
Effectiveness of a novel educational program on the quality of life and the clinical outcome.At 12 weeks, after 6 and 9 months

Therefore quality of life questionnaires are completed at the beginning of the program, at the end of the program (12 weeks), after 6 months and after 9 months. The quality of life questionnaires are Daily life quality index, Skindex 29, EuroQol -5D, Short Form - 36 , Psoriasis disability index, Quality of Life Index for Atopic Dermatitis.

The clinical effectiveness is determined by measuring psoriasis area and severity index (PASI) or scoring atopic dermatitis (SCORAD) at the beginning of the program, at the end of the program (12 weeks), after 6 months and after 9 months.

Secondary Outcome Measures
NameTimeMethod
Depression severityAt 12 weeks, 6 months and 9 months

Beck Depression Inventory (BDI) is a self-completed questionnaire with 21 questions. It is one of the most widely used instruments for measuring depression severity. BDI scores are collected during the four study visits.

LifestyleAt 12 weeks, 6 months and 9 months

Patients are queried for changes in smoking behaviour and physical activity monthly. Also, stress is examined during the four study visits,therefore we use the Everyday Problem Checklist.

Medical consumption and cost-effectiveness evaluationAt 12 weeks, 6 months and 9 months

Medical therapy of patients is divided into: topical therapy, systemic therapy, combination of topical and systemic therapy or no therapy. Patients are asked for changes in medical therapy monthly. Also, medical consumption is followed: costs for medication and doctor visits related to the management of the skin disease. EuroQol-5D (EQ-5D) questionnaires are used as standardised instrument to measure health outcomes. For cost-utility analysis, gain in quality-adjusted life years utilities is plotted against time, using the area under the curve approach (cost in EUR/EQ-5D gain).

Trial Locations

Locations (1)

University Hospital Ghent

🇧🇪

Ghent, Belgium

© Copyright 2025. All Rights Reserved by MedPath